Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule
US8030443B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2006 |
| Grant date | Oct 4, 2011 |
| Priority date | — |
| Expiry date | Feb 15, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/575
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.